https://pharmadog.xyz/news/596671 pharmadog en 2026-10-26T15:49:12.000Z Merck highlights oncology pipeline and cancer vaccine trial at ESMO 2026 https://pharmadog.xyz/news/596715 pharmadog en 2026-10-26T15:30:00.000Z Merck/Kelun ADC sac-TMT cuts death risk by one-third in advanced endometrial cancer https://pharmadog.xyz/news/596696 pharmadog en 2026-10-26T15:01:29.000Z J&J's Halda-derived prostate cancer drug shows 75% response in early Phase 1 trial https://pharmadog.xyz/news/596503 pharmadog en 2026-10-26T14:40:47.000Z Aspen Neuroscience and Bambusa Therapeutics each aim for $135 million IPOs https://pharmadog.xyz/news/596527 pharmadog en 2026-10-26T14:40:40.000Z Biotech IPOs Pull in $7.5B Across 22 Deals in 2026, While Market Gains Stall in Q3 https://pharmadog.xyz/news/596547 pharmadog en 2026-10-26T14:38:28.000Z Health insurance premiums surge as CMS ramps up Medicaid fraud crackdown https://pharmadog.xyz/news/596528 pharmadog en 2026-10-26T14:33:05.000Z Merck and Moderna's mRNA melanoma vaccine shows 42% risk reduction in Phase 3 trial, easing analyst concerns https://pharmadog.xyz/news/596529 pharmadog en 2026-10-26T14:29:08.000Z Amgen’s Imdelltra plus AstraZeneca’s Imfinzi cuts death risk by ~60% in extensive-stage small cell lung cancer https://pharmadog.xyz/news/134233 pharmadog en 2026-10-26T14:16:00.000Z CLINUVEL to cut up to 20% of staff and move headquarters to New York https://pharmadog.xyz/news/596504 pharmadog en 2026-10-26T14:11:34.000Z SystImmune/BMS and Hengrui showcase ADC data for EGFR-mutant lung cancer at ESMO https://pharmadog.xyz/news/596505 pharmadog en 2026-10-26T14:05:43.000Z Lilly Oncology President Jacob Van Naarden: A Music-Loving Dealmaker With Clear Vision https://pharmadog.xyz/news/596567 pharmadog en 2026-10-26T13:59:35.000Z Patient dies after receiving Bristol Myers experimental autoimmune CAR-T therapy zola-cel https://pharmadog.xyz/news/596379 pharmadog en 2026-10-26T13:57:14.000Z Incyte reports lasting tumor responses in pancreatic cancer patients using targeted drug plus chemotherapy https://pharmadog.xyz/news/596380 pharmadog en 2026-10-26T13:38:56.000Z Moderna and Merck aim to file personalized cancer vaccine for FDA approval after Phase 3 success https://pharmadog.xyz/news/596382 pharmadog en 2026-10-26T13:26:15.000Z First human case of cow-associated Shamonda virus reported in France https://pharmadog.xyz/news/596335 pharmadog en 2026-10-26T13:14:17.000Z Corxel Group to go public in US by merging with SPAC, targeting oral GLP-1 market https://pharmadog.xyz/news/596191 pharmadog en 2026-10-26T12:08:31.000Z Genmab’s Rina-S ADC cuts risk of progression and death in Phase 3 ovarian cancer trial https://pharmadog.xyz/news/595723 pharmadog en 2026-10-26T10:34:34.000Z BioNTech, DualityBio weigh future of HER2 ADC after modest Phase 3 breast cancer results https://pharmadog.xyz/news/595620 pharmadog en 2026-10-26T09:00:00.000Z Manufacturing hurdles grow as next-gen protein therapeutics gain traction https://pharmadog.xyz/news/595451 pharmadog en 2026-10-26T09:00:00.000Z Overlooked drugs can gain value when markets evolve, says Azurity CEO https://pharmadog.xyz/news/595431 pharmadog en 2026-10-26T09:00:00.000Z Experts unveil four-stage framework for women's heart health across the lifespan https://pharmadog.xyz/news/596142 pharmadog en 2026-10-26T08:40:00.000Z BioNTech's HER2-directed ADC shows modest benefit and higher lung toxicity in phase 3 trial https://pharmadog.xyz/news/595433 pharmadog en 2026-10-26T08:30:00.000Z NIH launches vaccine injury center that will also study long-term post-infection symptoms https://pharmadog.xyz/news/595434 pharmadog en 2026-10-26T08:30:00.000Z Patient feels exhausted despite normal labs, highlighting stress and lifestyle factors https://pharmadog.xyz/news/595435 pharmadog en 2026-10-26T08:30:00.000Z Researchers warn long-term AI use may foster social isolation, call for better data access https://pharmadog.xyz/news/595432 pharmadog en 2026-10-26T08:30:00.000Z Moderna CEO Bancel optimistic after Phase 3 success of mRNA melanoma vaccine intismeran https://pharmadog.xyz/news/595530 pharmadog en 2026-10-26T05:07:00.000Z Tango Therapeutics reports 82% response rate for PRMT5 inhibitor combo in pancreatic cancer trial https://pharmadog.xyz/news/596478 pharmadog en 2026-10-26T05:05:00.000Z Lycia Therapeutics raises $317.5 million in upsized Nasdaq IPO as Windward Bio eyes listing https://pharmadog.xyz/news/594631 pharmadog en 2026-10-26T04:02:00.000Z Taysha and Neurogene close in on first Rett syndrome gene therapy as 2027 readouts loom https://pharmadog.xyz/news/594632 pharmadog en 2026-10-26T04:01:00.000Z Australian clinical trials attract more U.S. sponsors amid regulatory uncertainty https://pharmadog.xyz/news/593235 pharmadog en 2026-10-25T21:43:13.000Z Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to Keytruda https://pharmadog.xyz/news/592223 pharmadog en 2026-10-25T16:58:45.000Z AstraZeneca highlights broad oncology portfolio at ESMO conference https://pharmadog.xyz/news/592012 pharmadog en 2026-10-25T15:30:51.000Z Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trial https://pharmadog.xyz/news/592013 pharmadog en 2026-10-25T15:30:09.000Z AstraZeneca reports Tagrisso-Orpathys combo could prolong treatment for EGFR-mutant lung cancer https://pharmadog.xyz/news/594078 pharmadog en 2026-10-25T12:03:00.000Z ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug https://pharmadog.xyz/news/596310 pharmadog en 2026-10-25T11:14:00.000Z Incyte reports strong early results for KRAS G12D inhibitor in pancreatic cancer, rivals RevMed https://pharmadog.xyz/news/591083 pharmadog en 2026-10-25T10:00:51.000Z Pfizer shifts focus after lung cancer trial setback, cites early signals in earlier-line patients; BioNTech and BMS report initial activity https://pharmadog.xyz/news/592156 pharmadog en 2026-10-25T09:47:00.000Z J&J touts promising RIPTAC data with 59% PSA reductions in prostate cancer trial https://pharmadog.xyz/news/590683 pharmadog en 2026-10-25T08:31:01.000Z Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trial https://pharmadog.xyz/news/588254 pharmadog en 2026-10-24T18:23:00.000Z Tonight We Ride recalls Ultimate Forza male supplement after finding undeclared sildenafil, tadalafil and dapoxetine